Synapse - Center for Hematologic Malignancies

Results (13553)

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Meeting Abstract

Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies

Meeting Abstract

Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K. Q.; Londhe, A.; Nair, S.; Lin, X. W.; Pei, L. X.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)

Meeting Abstract

Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity

Meeting Abstract

Locke, F. L.; Siddiqi, T.; Jacobson, C. A.; Ghobadi, A.; Ahmed, S.; Miklos, D. B.; Perales, M. A.; Munoz, J.; Logan, B.; Hu, Z. H.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access

Meeting Abstract

Kourelis, T.; Bansal, R.; Patel, K. K.; Berdeja, J. G.; Raje, N. S.; Alsina, M.; Cohen, A. D.; Siegel, D. S. D.; Mailankody, S.; Htut, M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Krishnan, A. Y.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X. W.; Qi, K. Q.; Londhe, A.; Pei, L. X.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm

Meeting Abstract

Kumar, S.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J. R.; Vij, R.; Ye, J. C.; Zonder, J. A.; DiLello, L.; Yesil, J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma

Meeting Abstract

Kersten, M. J.; Qiao, Y.; Shah, R.; Solem, C.; Snider, J.; To, C. A.; Cheng, P.; Spooner, C.; Perales, M. A.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma

Meeting Abstract

Kinnaman, M. D.; Zaccaria, S.; Makohon-Moore, A.; Gundem, G.; Ossa, J. E. A.; Bouvier, N.; Dela Cruz, F. S.; Hameed, M.; Bender, J. L. G.; Tap, W. D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save